DNA sequence recognition by the antitumor drug ditercalinium.
The antitumor drug ditercalinium is a rare example of a noncovalent DNA-binding ligand that forms bisintercalation complexes via the major groove of the double helix. Previous structural studies have revealed that the two connected pyridocarbazolium chromophores intercalate into DNA with the positively charged bis(ethylpiperidinium) linking chain oriented to the wide groove side of the helix. Although the interaction of ditercalinium with short oligonucleotides containing 4-6 contiguous GC base pairs has been examined in detail by biophysical and theoretical approaches, the sequence preference for ditercalinium binding to long DNA fragments that offer a wide variety of binding sites has been investigated only superficially. Here we have investigated both sequence preferences and possible molecular determinants of selectivity in the binding of ditercalinium to DNA, primarily using methods based upon DNase I footprinting. A range of multisite DNA substrates, including several natural restriction fragments and different PCR-generated fragments containing unconventional bases (2,6-diaminopurine, inosine, uridine, 5-fluoro- and 5-methylcytosine, 7-deazaguanine, 7-deazaadenine, and N(7)-cyanoboranoguanine), have been employed to show that ditercalinium selectively recognizes certain GC-rich sequences in DNA and to identify some of the factors which affect its DNA-binding sequence selectivity. Specifically, the footprinting data have revealed that the 2-amino group on the purines or the 5-methyl group on the pyrimidines is not essential for the formation of ditercalinium-DNA complexes whereas the major groove-oriented N(7) of guanine does appear as a key element in the molecular recognition process. The loss of N(7) at guanines but not adenines is sufficient to practically abolish sequence-selective binding of ditercalinium to DNA. Thus, as expected for a major groove binding drug, the N(7) of guanine is normally required for effective complex formation with GC base pairs, but interestingly the substitution of the N(7) with a relatively bulky cyanoborane group does not markedly affect the sequence recognition process. Therefore, the hydrogen bond accepting capability at N(7) of guanines is not sufficient to explain the GC-selective drug-DNA association, and the implications of these findings are considered.
Crow
Stephen D G
SD
Department of Pharmacology, University of Cambridge, Tennis Court Road, Cambridge CB2 1PD, UK.
Bailly
Christian
C
Garbay-Jaureguiberry
Christiane
C
Roques
Bernard
B
Shaw
Barbara Ramsay
BR
Waring
Michael J
MJ
D000970:Antineoplastic Agents / Q000493:pharmacokinetics*; D001483:Base Sequence; D001665:Binding Sites; D002227:Carbazoles / Q000493:pharmacokinetics*; D004247:DNA / Q000737:chemistry / Q000187:drug effects / Q000378:metabolism*; D018983:DNA Footprinting; D003850:Deoxyribonuclease I; D003854:Deoxyribonucleotides / Q000378:metabolism; D007364:Intercalating Agents; D008969:Molecular Sequence Data; D015183:Restriction Mapping; D013379:Substrate Specificity
D000970:Antineoplastic Agents; D002227:Carbazoles; D003854:Deoxyribonucleotides; D007364:Intercalating Agents; D004247:DNA; D003850:Deoxyribonuclease I; C042804:ditercalinium